Patent Application
20230270743
The present disclosure belongs to the field of medicine, and relates to a use of a BTK inhibitor for treating diseases.
Neuromyelitis optica (NMO, also known as Devic syndrome) is a rare, chronic, autoimmune, inflammatory central nervous system (CNS) demyelinating disease that affects the optic nerve and spinal cord. It is characterized by recurrent episodes of optic neuritis and longitudinally extensive transverse myelitis (LETM), which may occur simultaneously or independently.
Clinical features of NMO include optic neuritis with vision loss leading to blindness, as well as eye pain, optic atrophy, and central scotoma. Spinal cord involvement includes paraparesis or quadriparesis, radicular pain, paroxysmal tonic spasms, nausea, intractable hiccups, vomiting, vertigo, bladder dysfunction, and Lhermitte's phenomenon. Clinical features associated with lesions other than the optic nerve and spinal cord lesions may include excessive sleepiness associated with hypothalamic-pituitary axis insufficiency, hyponatremia and hyperprolactinemia, and reversible posterior encephalopathy syndrome. Up to 90% of NMO patients have recurrent optic neuritis (ON) and myelitis rather than a monophasic course. 60% of patients relapse within 1 year after onset, and 90% of patients relapse within 3 years after onset.
Previously, NMO was considered a subtype of multiple sclerosis (MS), which has symptoms overlapping with NMO. However, NMO has now been proven to be a unique demyelinating disease different from MS. Unlike MS, recovery between episodes of NMO is incomplete, with each succeeding episode leading to increased disability. The antigenic target, aquaporin 4 (AQP4), was not identified until 2004. The two diseases could be reliably distinguished by detection of antibodies to AQP4. Later, an update of the diagnostic guidelines classified antibody-negative and antibody-positive NMOs into neuromyelitis optica spectrum disorders (NMOSD). Although case series studies and observational studies have shown that patients benefit from immunotherapy, only 2 therapies (Eculizumab and Satralizumab) have been approved to treat NMOSD to date.
AQP4 is the most widely expressed aquaporin in the brain, spinal cord and optic nerve. Experimental data showed that antibodies to AQP4 induced the production of interleukin 6 (IL-6) in AQP4-expressing astrocytes, and IL-6 signaling to endothelial cells reduced blood-brain barrier function. Once the antibody to AQP4 binds to the ectodomain of the AQP4 receptor, it not only causes the internalization of the glutamate transporter EAAT-2, but also causes complement and cell-mediated astrocyte damage. Astrocytes eventually no longer support surrounding cells such as oligodendrocytes and neurons. Then granulocytic infiltration occurs, with oligodendrocyte injury and demyelination.
Immune cells can usually be divided into T cells and B cells. The main function of B cells is to secrete various antibodies to help the body resist various foreign invasions. Bruton's tyrosine kinase (BTK) is one of the members of the tyrosine kinase subfamily, and belongs to the Tec family of kinases. It is mainly expressed in B cells, and distributed in the lymphatic system, hematopoietic and blood systems. B cell receptor (BCR) plays a crucial role in regulating the proliferation and survival of various lymphomas including chronic lymphocytic leukemia (CLL) and subtypes of non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). In addition, the role of B cells in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and other immune diseases has been clinically confirmed. Bruton's tyrosine kinase (BTK) is a key protein kinase in the BCR signaling pathway. It can regulate the maturation and differentiation of normal B cells, and is also closely related to a variety of B cell lymphoid tissue disorders. Therefore, small-molecule inhibitors targeting BTK may provide benefits in the treatment of B-cell malignancy and autoimmune disease.
WO2016007185 relates to a compound of formula (I), namely (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one. The compound is a novel BTK kinase inhibitor, which has improved kinase selectivity, clinical efficacy or indications, and safety. Its structure is as follows:
The present disclosure provides a use of a BTK inhibitor for treating or preventing diseases, and shows good therapeutic effect.
In an aspect, the present disclosure provides a use of a BTK inhibitor in the preparation of a medicament for preventing or treating neuromyelitis optica spectrum disorder.
In another aspect, the present disclosure provides a use of a BTK inhibitor in the preparation of a medicament for preventing relapse of neuromyelitis optica spectrum disorder.
In another aspect, the present disclosure provides a use of a BTK inhibitor in the preparation of a medicament for treating stable phase of neuromyelitis optica spectrum disorder.
The stable phase of the neuromyelitis optica spectrum disorder refers to the phase when the condition of the neuromyelitis optica spectrum disorder is alleviated after the rescue therapy is carried out in the acute attack phase. For example, when treating with the BTK inhibitor, the dose of the maintenance drug such as immunosuppressant (such as tacrolimus, azathioprine, mycophenolate) and/or oral corticosteroid must be stable or in the process of reduction, and the rescue therapy (such as IV glucocorticoid, plasma exchange, and/or intravenous immunoglobulin) must be completed for more than 1 month.
In some embodiments, the BTK inhibitor is selected from the group consisting of ibrutinib, acalabrutinib, GS-4059, spebrutinib, BGB-3111, FIM71224, zanubrutinib, ARQ531, BI-BTK1, vecabrutinib and a compound of formula (I) or a pharmaceutically acceptable salt thereof,
In some embodiments, the BTK inhibitor is the compound of formula (I) or a pharmaceutically acceptable salt thereof,
The compound of the present disclosure can also exists in different tautomeric forms, all tautomeric forms are within the scope of the present disclosure. The term “tautomer” or “tautomeric form” refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomer (also known as prototropic tautomer) includes interconversion via migration of a proton, such as keto-enol and imine-enamine isomerizations. An example of a lactam-lactim equilibrium is an equilibrium between A and B as shown below.
In some embodiments, the compound of formula (I) of the present disclosure can be drawn as type A or type B. The naming of compounds does not exclude any tautomers. The clinical manifestations of the neuromyelitis optica spectrum disorder described in the present disclosure include optic neuritis, myelitis, area postrema syndrome, brainstem syndrome, diencephalic syndrome, cerebral syndrome, and the like.
In some embodiments, the neuromyelitis optica spectrum disorder is an AQP4-IgG positive neuromyelitis optica spectrum disorder.
In some embodiments, the dose of the BTK inhibitor is 1 to 1000 mg, for example, can be 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg. The administration frequency can be once a day, twice a day, three times a day, once every two days, once every three days, once a week, and the like.
In some embodiments, the administration frequency of the BTK inhibitor is once a day, and the dose is 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg each time.
In some embodiments, the administration frequency of the BTK inhibitor is twice a day, and the dose is 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg each time.
The pharmaceutically acceptable salt of the drug of the present disclosure can be hydrochloride, phosphate, hydrophosphate, sulfate, bisulfate, sulfite, acetate, oxalate, malonate, valerate, glutamate, oleate, palmitate, stearate, laurate, borate, p-toluenesulfonate, mesylate, isethionate, maleate, malate, tartrate, benzoate, pamoate, salicylate, vanillate, mandelate, succinate, gluconate, lactobionate, lauryl sulfonate, and the like.
The BTK inhibitor of the present disclosure can also be administered in combination with other drugs. The combined administration mode is selected from the group consisting of simultaneous administration, co-administration after separate formulation, and sequential administration after separate formulation.
The administration route of the drug of the present disclosure is selected from the group consisting of oral administration, parenteral administration and transdermal administration. The parenteral administration includes, but is not limited to, intravenous injection, subcutaneous injection, and intramuscular injection.
The disclosure further relates to a method for treating neuromyelitis optica spectrum disorder, comprising administering a BTK inhibitor to a patient.
In some embodiments, the present disclosure relates to a method for treating neuromyelitis optica spectrum disorder, comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient.
The present disclosure further relates to the compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating neuromyelitis optica spectrum disorder.
The present disclosure further relates to a method for preventing relapse of neuromyelitis optica spectrum disorder, comprising administering a BTK inhibitor to a patient.
In some embodiments, the present disclosure relates to a method for preventing relapse of neuromyelitis optica spectrum disorder, comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient.
The present disclosure further relates to a BTK inhibitor for use in preventing relapse of neuromyelitis optica spectrum disorder.
In some embodiments, the present disclosure relates to the compound of formula (I) or a pharmaceutically acceptable salt thereof for use in preventing relapse of neuromyelitis optica spectrum disorder.
The present disclosure further relates to a method for treating stable phase of neuromyelitis optica spectrum disorder, comprising administering a BTK inhibitor to a patient.
In some embodiments, the present disclosure relates to a method for treating stable phase of neuromyelitis optica spectrum disorder, comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient.
The present disclosure further relates to a BTK inhibitor for use in treating stable phase of neuromyelitis optica spectrum disorder.
In some embodiments, the present disclosure relates to the compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating stable phase of neuromyelitis optica spectrum disorder.
The present disclosure also relates to a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients and diluents. The pharmaceutical composition can be formulated into any pharmaceutically acceptable dosage form. For example, the pharmaceutical composition can be formulated into a tablet, capsule, pill, granule, solution, suspension, syrup, injection (including injection solution, sterile powder for injection and concentrated solution for injection), suppository, inhalant or spray.
The present disclosure also provides a pharmaceutical packaging box, in which the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof of the present disclosure is packaged.
A “therapeutically effective amount” refers to the amount of a therapeutic agent that produces the desired effect for which it is administered. In some embodiments, the term refers to an amount sufficient to treat a disease, disorder and/or condition when administered according to a regimen to a population suffering from or susceptible to the disease, disorder and/or condition. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence and/or severity of, and/or delays the onset of, one or more symptoms of a disease, disorder and/or condition. Those of ordinary skill in the art will appreciate that the term “therapeutically effective amount” actually does not need to achieve successful treatment in a particular individual. Conversely, a therapeutically effective amount can be an amount that, when administered to a patient in need of such treatment, provides a specific desired pharmacological response in a substantial number of subjects. In some embodiments, a reference to a therapeutically effective amount can refer to an amount as measured in one or more particular tissues (such as tissues affected by a disease, disorder or condition) or fluid (such as blood, saliva, serum, sweat, tears, urine, and the like). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount of a particular agent or therapy can be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective agent can be formulated and/or administered in multiple doses, for example, as part of a regimen.
Average annualized relapse rate (ARR)=total number of episodes of subjects/(number of subjects*observation time).
The achievable effect of the compound of formula (I) or a pharmaceutically acceptable salt of the present disclosure in treating neuromyelitis optica spectrum disorder is that the subject's ARR<2.1 after baseline medication.
The achievable effect of the compound of formula (I) or a pharmaceutically acceptable salt of the present disclosure in treating neuromyelitis optica spectrum disorder is that the subject's ARR after baseline medication can be selected from the group consisting of 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 2.0.
1. Experimental Drug
Tablets of the compound of formula (I), specification: 100 mg/tablet.
2. Enrollment Criteria
1) Male or female from 18 to 75 years old (including 18 and 75 years old);
2) Patients diagnosed with AQP4-IgG positive NMOSD according to the 2015 IPND diagnostic criteria;
3) Requirements for history of relapse: 2 or more relapses of NMOSD requiring rescue therapy within 1 year before baseline, the rescue therapy can include IV glucocorticoid, plasma exchange, and/or intravenous immune globulin (IVIG);
4) Subjects must have been on stable treatment (if any) for more than 1 month before starting test drug treatment, defined as follows:
2. Administration Regimen
The test drug was administered to the qualified subjects in the morning on an empty stomach, once a day, one tablet at a time, and 100 mg per tablet.
3. Experimental Results
At present, the study has completed the enrollment of all 10 subjects, and the average annualized relapse rate (ARR=the total number of episodes of subjects/(number of subjects*observation time)) of all subjects before enrollment was 2.1. By now, an annualized relapse rate of 0.7 for existing subjects after baseline medication has been observed. A 42-year-old female patient with a 7-year history of NMOSD had severe symptoms (unable to stand) before participating in the trial. After administering the compound of formula (I) for 4 weeks, the patient obtained significantly improved mobility, and could stand up and walk several steps with assistance. At the 7th week of medication, the patient could walk more than 20 meters with assistance, and could substantially take care of herself.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202010796482.1 | Aug 2020 | CN | national |
| 202110295378.9 | Mar 2021 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2021/111726 | 8/10/2021 | WO |
